About Us

Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006 and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection.

Oramed has an experienced management team with many years of business and pharmaceutical experience and is backed by world-class scientific experts.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of people around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier – without fear of needles.

Oramed’s oral insulin is currently in clinical trials under the US FDA for the treatment of type 2 diabetes.

In addition to oral insulin, the Company’s proprietary POD™ technology can potentially be used to orally administer a number of protein-based therapies, which are currently available only via injection.

Successfully Tested Technology

Oramed has successfully tested its technology via various pre-clinical and clinical studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog capsule, ORMD-0901.

Meet The Team

MANAGEMENT
BOARD OF DIRECTORS

Ben Shapiro

Director

Ben Shapiro has been an Oramed director since May 2023.

He is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of “The Ben Shapiro Show,” a popular podcast, and he is the author of numerous New York Times best-selling books.

Mr. Shapiro earned a B.A. in Political Science from UCLA in 2004, summa cum laude, and a law degree from Harvard Law School in 2007, cum laude.

Leonard Sank

Director

Mr. Sank has been an Oramed director since 2007.

He is an entrepreneur and businessman, based in South Africa, who is devoted to entrepreneurial endeavors and initiatives.

Mr. Sank has over 20 years of experience in important leadership roles in building and developing businesses and he serves on the Board of Directors of several other companies in a variety of sectors.

Arie Mayer, Ph.D

Director

Dr. Mayer has been an Oramed director since 2019.

Dr. Mayer is the Managing Director and Chairman of the Board of Merck Life Science Israel (formerly Sigma-Aldrich Israel Ltd.) and has held that position since January 2010. He has held various roles with Sigma-Aldrich Israel Ltd. since 1995 and was instrumental in introducing and developing the Cell Culture and Molecular Biology business for Sigma Aldrich Israel.

Dr. Mayer holds a Bachelor of Science in chemistry from Hebrew University and a Ph.D. in biochemistry from Israel Institute of Technology and has publications as a main author in Science, Journal of Biological Chemistry, New Scientist and the Journal of Cell Sciences.

Nadav Kidron, Esq

Chief Executive Officer,
President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006. 

Oramed is the first company to conduct Phase 3 trials under the FDA for oral insulin.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries. He co-founded Oravax Medical as a joint-venture with Oramed and Premas Biotech and currently serves as the Chairman of the Board. Oravax is dedicated to bringing an oral Covid-19 vaccine to market. He also co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

Mr. Kidron holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

Miriam Kidron, Ph.D

Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Daniel Aghion

Director

Dr. Daniel Aghion has been an Oramed director since January 2024.

Dr. Aghion is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more.

Dr. Aghion holds a Bachelor’s of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.

SCIENTIFIC ADVISORY BOARD

Roy Eldor, M.D., Ph.D.

Dr. Eldor joined the Oramed Scientific Advisory Board in July 2016. He is an endocrinologist, internist and researcher with over twenty years of clinical and scientific experience. He is currently Director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension at the Tel-Aviv Sourasky Medical Center. Prior to that, Dr. Eldor served as Principal Scientist at Merck Research Laboratories, Clinical Research – Diabetes & Endocrinology. He previously served as a senior physician in internal medicine at the Diabetes Unit in Hadassah Hebrew University Hospital in Jerusalem, Israel; and the Diabetes Division at the University of Texas Health Science Center in San Antonio, Texas. Dr. Eldor is a recognized expert, with over 50 peer reviewed papers and book chapters, and has been a guest speaker at numerous international forums.

Ele Ferrannini, M.D. Ph.D.

Professor Ferrannini joined the Oramed Scientific Advisory Board in February 2007. He is a past President to the European Association for the Study of Diabetes (EASD), which supports scientists, physicians and students from all over the world who are interested in diabetes and related subjects in Europe and performs functions similar to that of the American Diabetes Association in the United States. Professor Ferrannini has worked with various institutions including the Department of Clinical & Experimental Medicine at the University of Pisa School of Medicine, and CNR (National Research Council) Institute of Clinical Physiology in Pisa, Italy; and the Diabetes Division, Department of Medicine at the University of Texas Health Science Center in San Antonio, Texas. He has extensive training in internal medicine and endocrinology, and has specialized in diabetes trials. Professor Ferrannini has received a Certificate of the Educational Council for Foreign Medical Graduates from the University of Bologna, and completed a subspecialty in Diabetes and Metabolic Diseases at the University of Torino, cum laude. He has published over 500 original papers and 50 book chapters and he is a “highly cited researcher,” according to the Institute for Scientific Information.

Avram Hershko, M.D. Ph.D

Professor Hershko joined the Oramed Scientific Advisory Board in July 2008. Professor Hershko served as a physician in the Israel Defense Forces from 1965 to 1967. After a post-doctoral fellowship with Gordon Tomkins at the University of San Francisco from 1969 to 1972, he joined the faculty of the Haifa Technion becoming a professor in 1980. He is now Distinguished Professor in the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion in Haifa, Israel. Professor Hershko’s main research interests concern the mechanisms by which cellular proteins are degraded, a formerly neglected field of study. Professor Hershko and his colleagues showed that cellular proteins are degraded by a highly selective proteolytic system. This system tags proteins for destruction by linkage to a protein called ubiquitin, which had previously been identified in many tissues, but whose function was previously unknown. Subsequent work by Professor Hershko and many other laboratories has shown that the ubiquitin system has a vital role in controlling a wide range of cellular processes, such as the regulation of cell division, signal transduction and DNA repair. Professor Hershko was awarded the Nobel Prize in Chemistry in 2004, jointly with his former PhD student Aaron Ciechanover and their colleague Irwin Rose. His many honors include the Israel Prize for Biochemistry (1994), the Gairdner Award (1999), the Lasker Prize for Basic Medical Research (2000), the Wolf Prize for Medicine (2001) and the Louisa Gross Horwitz Award (2001). Professor Hershko is a member of the Israel Academy of Sciences since 2000 and a Foreign Associate of the U.S. Academy of Sciences since 2003.

Harold Jacob, MD

Dr. Jacob joined the Oramed Scientific Advisory Board in November 2016. Since 1998, Dr. Jacob has served as the president of Medical Instrument Development Inc., a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting its own proprietary medical devices. Since 2011, Dr. Jacob has also served as an attending physician at Hadassah University Medical Center in Jerusalem, Israel, where he has served as the director of the gastrointestinal endoscopy unit since September 2013. Dr. Jacob has advised a spectrum of companies in the past and he served as a consultant and then as the Director of Medical Affairs at Given Imaging Ltd., from 1997 to 2003, a company that developed the first swallowable wireless pill camera for inspection of the intestine. He has licensed patents to a number of companies including Kimberly-Clark Corporation. Since 2014, Dr. Jacob has served as the Chief Medical Officer and a director of NanoVibronix, Inc., a medical device company using surface acoustics to prevent catheter acquired infection as well as other applications, where he served as Chief Executive Officer from 2004 to 2014. He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. John’s Episcopal Hospital and South Nassau Communities Hospital from 1986 to 1995, and was a Clinical Assistant Professor of Medicine at SUNY from 1983 to 1990. Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology.

Alexander Fleming, MD

Dr. Fleming joined the Oramed Scientific Advisory Board in December 2019. Dr. Fleming, an endocrinologist, is Founder and Executive Chairman of Kinexum, a strategic advisory firm. From 1986 to 1998, he served at the FDA as a supervisory medical officer in the Division of Metabolism and Endocrine Drug Products and was responsible for landmark approvals of the first statin, metformin, and other endocrine and metabolic therapies. He also represented the FDA at the World Health Organization and on multiple expert working groups of the International Conference on Harmonization (ICH). Dr. Fleming coined the term, Metabesity, which refers to the constellation of major chronic diseases and the aging process itself, all which share common metabolic root causes and potential preventive therapies. He organized the first Congress on Metabesity in London in October 2017, followed by annual conferences. In 2020, Dr. Fleming founded the non-profit Kitalys Institute as a means of producing Metabesity conferences and advancing interventions of any kind that can improve health and healthspan.

Julio Rosenstock, MD

Dr. Rosenstock joined the Oramed Scientific Advisory Board in January 2020. Dr. Rosenstock is the Senior Scientific Advisor and Director of Velocity Clinical Research at Medical City, Dallas, Texas, and a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center in Dallas, Texas. He is board certified in Internal Medicine, Endocrinology and Metabolism. His clinical and research activities have focused on exploring novel agents and therapeutic strategies to improve glycemic control, particularly early combination therapies in Type 2 Diabetes. Over the last 30 years, he has participated in hundreds of clinical trials and has had an active role in the development of new oral agents, incretin-related therapies and insulin formulations, often acting as a lead clinical investigator and scientific advisor on the design and reporting of these clinical trials. Dr. Rosenstock has been the author or co-author of 360 peer-reviewed manuscripts (H-index 119) and several hundreds of scientific abstracts. He has also contributed to 13 book chapters on various topics in the field of diabetes and is considered a key opinion leader in Type 2 Diabetes.

Jay Skyler, MD, MACP

Dr. Skyler joined the Oramed Scientific Advisory Board in January 2020. Dr. Skyler is Professor of Medicine, Pediatrics and Psychology in the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Leonard M. Miller School of Medicine. He previously held the position of Director of the Division of Endocrinology, Diabetes and Metabolism. In addition, Dr. Skyler is Deputy Director of Clinical Research and Academic Programs at the Diabetes Research Institute, and an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado in Denver. Dr. Skyler’s research focuses on the clinical aspects of diabetes, specifically the conduct of randomized controlled clinical trials. From 1993 to 2015, he was Chairman of the National Institute of Health (NIDDK)-sponsored Diabetes Prevention Trial–- Type 1 (DPT-1) and its successor Type 1 Diabetes Trial Net, a nationwide and global network conducting clinical trials to prevent T1D.

Anne Peters, MD

Dr. Peters joined the Oramed Scientific Advisory Board in June 2022. Dr. Peters is Professor of Medicine at the Keck School of Medicine of the University of Southern California (USC) and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes programs at Cedars-Sinai Medical Center and UCLA in California. Her research has focused on testing new approaches for diagnosing and treating diabetes and developing systems of care to improve outcomes in diabetic populations. Dr. Peters is the chair of the Endocrine Society Committee on Diabetes Devices and is on the EASD/ADA Technology Safety Committee. Additionally, she is a member of the JDRF Panel on Management of Exercise in type 1 Diabetes and a member of the ABIM Endocrinology Subspecialty Board. Dr. Peters has consulted for many entities, including the FDA, Optum Rx and CVS/Caremark to help guide the development and use of treatments for diabetes. In addition to being an investigator for more than 40 research studies, Dr. Peters has published over 200 articles, has written four books, and has given more than 500 lectures locally, nationally, and internationally. She has been on multiple guideline writing committees for the treatment of both type 1 and type 2 diabetes. She was a recipient of the ADA Outstanding Physician Clinician Award, the Bernardo Houssay Award from the National Minority Quality Forum and received a 2021 Endocrine Society Laureate Award for Public Service. 

Nadav Kidron, Esq

Chief Executive Officer, President & Director

Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006. Oramed is the first company to conduct Phase 3 trials under the FDA for oral insulin.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries. He co-founded Oravax Medical as a joint-venture with Oramed and Premas Biotech and currently serves as the Chairman of the Board. Oravax is dedicated to bringing an oral Covid-19 vaccine to market. He also co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

Mr. Kidron holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

FOLLOW NADAV:

Miriam Kidron, Ph.D

Chief Scientific Officer & Director

Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Josh Hexter

Chief Operating and Business Officer

Mr. Hexter serves as Chief Operating and Business Officer of Oramed Pharmaceuticals. Mr. Hexter has nearly two decades of prominent leadership, business development and operations know-how, entrepreneurialism and management experience in the life science sector.

Prior to his current position, Mr. Hexter was Chief Business Officer of BrainsWay Ltd. (NASDAQ/TASE: BWAY). Previously, he served as the Chief Operating Officer of Oramed. Mr. Hexter has also served as Executive Director of Corporate In-Licensing at BioLineRx (NASDAQ/TASE: BLRX) and in the private equity and venture capital sector where he served as CEO of a VC-backed start-up. As founder and CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging strategic agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security.

Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.

FOLLOW JOSH:

David Silberman

Chief Financial Officer

Mr. Silberman serves as Chief Financial Officer of Oramed Pharmaceuticals.  He joined Oramed in 2021.  From 2018 until 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis Director at Teva Pharmaceutical Industries Ltd., a global pharmaceutical company. From 2014 to 2018, Mr. Silberman served as Global Internal Audit Senior Manager at Teva Pharmaceutical Industries Ltd.. From 2009 to 2014, Mr. Silberman provided internal audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. Prior to that, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm.

Mr. Silberman holds a DCG and a DSCG degrees from the French Ministry of Higher Education and Research and is a certified public accountant in Israel.

FOLLOW DAVID:

Netanel Derovan

Chief Legal Officer

Mr. Derovan serves as Chief Legal Officer of Oramed Pharmaceuticals. He is a highly accomplished executive leader, having spent over 20 years in senior legal positions.

Prior to joining Oramed, Mr. Derovan served as executive counsel, corporate and securities, in the legal department of Teva Pharmaceutical Industries Ltd., as senior counsel in the International Corporate and Securities Department of Goldfarb Seligman & Co. and as an associate attorney in the International Corporate Department at Caspi & Co.

Mr. Derovan holds an LLB degree from Bar Ilan University in Israel and he is a member of the Israeli Bar Association.

FOLLOW NETANEL:

Join our mailing list

Skip to content